Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol

Abstract

[...]protocol requires at least 10 days of treatment to obtain pituitary desensitization and FSH stimulation may induce a higher ovarian response and a higher risk of ovarian hyperstimulation syndrome (OHSS) than with GnRH antagonist protocols [1]. Since the development of the GnRH antagonists for the prevention of premature LH surges, most patients are treated with a GnRH antagonist protocol which is short, simple and convenient for the patient [2]. Randomized clinical trials have demonstrated that the GnRH antagonist protocol recruits a smaller number of follicles with lower serum oestradiol and, therefore, the risk of OHSS following triggering of final follicular maturation with human choriogonadotropin (hCG) is lower [3]. [...]in high responders the risk of OHSS can be largely mitigated by triggering final follicular maturation with a GnRH agonist instead of hCG [4]. Materials and methods Study design and participants This is a subset analysis including all 104 patients participating in a European Phase 2 dose-range trial and treated with individualized follitropin delta dosing plus placebo in a long GnRH agonist protocol as previously described [13]. Women (30–42 years) who were undergoing their first or second IVF/intracytoplasmic sperm injection (ICSI) cycle due to unexplained infertility, tubal infertility, endometriosis Stage I/II, or with partners diagnosed with male factor infertility, were eligible for the trial.